Teva Appoints Angus Grant, PhD, as EVP of Business Development
The pharma and biotech exec will begin his role on Aug. 1.
Teva Pharmaceutical Industries Ltd. has appointed of Angus Grant, PhD. as EVP, business development. He will start in his role on Aug. 1, and will be based out of Teva's US headquarters in Parsippany, NJ.
Grant joins Teva with over 25 years of experience in the global pharmaceutical and biotech industry, with a track record across a variety of fields including business development, R&D, and regulatory affairs. Most recently, He was the chief business executive at BeiGene, overseeing business development, clinical and business insights and valuation, investments and collaborations, and alliance management. Before his tenure at BeiGene, Grant served as CEO of the Dementia Discovery Fund (DDF), a specialist venture capital fund focused on therapeutics for age-related dementias and neurodegenerative disease. Earlier in his career, Grant spent 12 years at Celgene, serving in various leadership roles including corporate VP of business development, and VP, regulatory affairs.
“We are pleased to welcome a leader of Angus’ caliber to our executive team at Teva,” comments Richard Francis, Teva’s president and CEO. “With a distinguished career spanning over more than two and a half decades in the global pharmaceutical and biotech industry, his breadth of experience and demonstrated expertise in business development, innovative R&D, and scientific affairs will be a significant asset to our organization.
